Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Massimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, Giuseppe A. Palumbo, Nicola Polverelli, Elisabetta Abruzzese, Micaela Bergamaschi, Alessia Tieghi, Mario Tiribelli, Alessandra Iurlo, Francesco Cavazzini, Nicola Sgherza, Gianni Binotto, Alessandro Isidori, Mariella D’Adda, Monica Crugnola, Costanza Bosi, Florian Heidel, Matteo Molica, Luigi ScaffidiDaniele Cattaneo, Roberto Latagliata, Giuseppe Auteri, Roberto M. Lemoli, Renato Fanin, Domenico Russo, Franco Aversa, Antonio Cuneo, Gianpietro Semenzato, Lucia Catani, Michele Cavo, Nicola Vianelli, Robin Foà, Francesca Palandri

Research output: Contribution to journalArticle

Abstract

Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index (BMI) are significantly associated with outcome in patients who receive continuous treatment with tyrosine kinase inhibitors. We evaluated the impact of CCI and BMI on responses, drug-related toxicities, and outcome in a cohort of 402 patients with myelofibrosis (MF) treated with ruxolitinib in 23 European Hematology Centers. Comorbidities were evaluable in all 402 patients. A higher (≥ 3) CCI did not correlate with a lower spleen reduction at any time (p = 0.68) or symptoms’ response (p = 0.11), but influenced the onset of anemia during the first 3 months of treatment and later (p = 0.02 and p = 0.03, respectively) in patients without anemia baseline. BMI was evaluable in 380 patients and did not correlate with differences in spleen and symptoms response (p = 0.57 and p = 0.49, respectively). A higher CCI and a lower BMI correlated also with a reduced overall survival (p < 0.001 and p = 0.02, respectively). The achievement of a spleen response at 6 months could counterbalance the negative impact of comorbidities, while patients who were underweight when starting ruxolitinib and did not achieve a spleen response at 6 months were projected to the worse outcome. In MF patients treated with ruxolitinib, BMI and comorbidities did not influence the achievement of spleen/symptom responses, but they contributed to the early identification of patients who deserve a strict monitoring during treatment.

Original languageEnglish
Pages (from-to)889-896
JournalAnnals of Hematology
Volume98
Issue number4
DOIs
Publication statusPublished - 2019

Fingerprint

Primary Myelofibrosis
Comorbidity
Body Mass Index
Spleen
Anemia
INCB018424
Thinness
Hematology
Drug-Related Side Effects and Adverse Reactions
Protein-Tyrosine Kinases
Therapeutics
Survival

Keywords

  • BMI
  • CCI
  • Comorbidities
  • Myelofibrosis
  • Ruxolitinib

ASJC Scopus subject areas

  • Hematology

Cite this

Breccia, M., Bartoletti, D., Bonifacio, M., Palumbo, G. A., Polverelli, N., Abruzzese, E., ... Palandri, F. (2019). Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 98(4), 889-896. https://doi.org/10.1007/s00277-018-3569-1

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. / Breccia, Massimo; Bartoletti, Daniela; Bonifacio, Massimiliano; Palumbo, Giuseppe A.; Polverelli, Nicola; Abruzzese, Elisabetta; Bergamaschi, Micaela; Tieghi, Alessia; Tiribelli, Mario; Iurlo, Alessandra; Cavazzini, Francesco; Sgherza, Nicola; Binotto, Gianni; Isidori, Alessandro; D’Adda, Mariella; Crugnola, Monica; Bosi, Costanza; Heidel, Florian; Molica, Matteo; Scaffidi, Luigi; Cattaneo, Daniele; Latagliata, Roberto; Auteri, Giuseppe; Lemoli, Roberto M.; Fanin, Renato; Russo, Domenico; Aversa, Franco; Cuneo, Antonio; Semenzato, Gianpietro; Catani, Lucia; Cavo, Michele; Vianelli, Nicola; Foà, Robin; Palandri, Francesca.

In: Annals of Hematology, Vol. 98, No. 4, 2019, p. 889-896.

Research output: Contribution to journalArticle

Breccia, M, Bartoletti, D, Bonifacio, M, Palumbo, GA, Polverelli, N, Abruzzese, E, Bergamaschi, M, Tieghi, A, Tiribelli, M, Iurlo, A, Cavazzini, F, Sgherza, N, Binotto, G, Isidori, A, D’Adda, M, Crugnola, M, Bosi, C, Heidel, F, Molica, M, Scaffidi, L, Cattaneo, D, Latagliata, R, Auteri, G, Lemoli, RM, Fanin, R, Russo, D, Aversa, F, Cuneo, A, Semenzato, G, Catani, L, Cavo, M, Vianelli, N, Foà, R & Palandri, F 2019, 'Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib', Annals of Hematology, vol. 98, no. 4, pp. 889-896. https://doi.org/10.1007/s00277-018-3569-1
Breccia, Massimo ; Bartoletti, Daniela ; Bonifacio, Massimiliano ; Palumbo, Giuseppe A. ; Polverelli, Nicola ; Abruzzese, Elisabetta ; Bergamaschi, Micaela ; Tieghi, Alessia ; Tiribelli, Mario ; Iurlo, Alessandra ; Cavazzini, Francesco ; Sgherza, Nicola ; Binotto, Gianni ; Isidori, Alessandro ; D’Adda, Mariella ; Crugnola, Monica ; Bosi, Costanza ; Heidel, Florian ; Molica, Matteo ; Scaffidi, Luigi ; Cattaneo, Daniele ; Latagliata, Roberto ; Auteri, Giuseppe ; Lemoli, Roberto M. ; Fanin, Renato ; Russo, Domenico ; Aversa, Franco ; Cuneo, Antonio ; Semenzato, Gianpietro ; Catani, Lucia ; Cavo, Michele ; Vianelli, Nicola ; Foà, Robin ; Palandri, Francesca. / Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. In: Annals of Hematology. 2019 ; Vol. 98, No. 4. pp. 889-896.
@article{6bb4cd9f8c414690b1d09d2e5c026be4,
title = "Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib",
abstract = "Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index (BMI) are significantly associated with outcome in patients who receive continuous treatment with tyrosine kinase inhibitors. We evaluated the impact of CCI and BMI on responses, drug-related toxicities, and outcome in a cohort of 402 patients with myelofibrosis (MF) treated with ruxolitinib in 23 European Hematology Centers. Comorbidities were evaluable in all 402 patients. A higher (≥ 3) CCI did not correlate with a lower spleen reduction at any time (p = 0.68) or symptoms’ response (p = 0.11), but influenced the onset of anemia during the first 3 months of treatment and later (p = 0.02 and p = 0.03, respectively) in patients without anemia baseline. BMI was evaluable in 380 patients and did not correlate with differences in spleen and symptoms response (p = 0.57 and p = 0.49, respectively). A higher CCI and a lower BMI correlated also with a reduced overall survival (p < 0.001 and p = 0.02, respectively). The achievement of a spleen response at 6 months could counterbalance the negative impact of comorbidities, while patients who were underweight when starting ruxolitinib and did not achieve a spleen response at 6 months were projected to the worse outcome. In MF patients treated with ruxolitinib, BMI and comorbidities did not influence the achievement of spleen/symptom responses, but they contributed to the early identification of patients who deserve a strict monitoring during treatment.",
keywords = "BMI, CCI, Comorbidities, Myelofibrosis, Ruxolitinib",
author = "Massimo Breccia and Daniela Bartoletti and Massimiliano Bonifacio and Palumbo, {Giuseppe A.} and Nicola Polverelli and Elisabetta Abruzzese and Micaela Bergamaschi and Alessia Tieghi and Mario Tiribelli and Alessandra Iurlo and Francesco Cavazzini and Nicola Sgherza and Gianni Binotto and Alessandro Isidori and Mariella D’Adda and Monica Crugnola and Costanza Bosi and Florian Heidel and Matteo Molica and Luigi Scaffidi and Daniele Cattaneo and Roberto Latagliata and Giuseppe Auteri and Lemoli, {Roberto M.} and Renato Fanin and Domenico Russo and Franco Aversa and Antonio Cuneo and Gianpietro Semenzato and Lucia Catani and Michele Cavo and Nicola Vianelli and Robin Fo{\`a} and Francesca Palandri",
year = "2019",
doi = "10.1007/s00277-018-3569-1",
language = "English",
volume = "98",
pages = "889--896",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

AU - Breccia, Massimo

AU - Bartoletti, Daniela

AU - Bonifacio, Massimiliano

AU - Palumbo, Giuseppe A.

AU - Polverelli, Nicola

AU - Abruzzese, Elisabetta

AU - Bergamaschi, Micaela

AU - Tieghi, Alessia

AU - Tiribelli, Mario

AU - Iurlo, Alessandra

AU - Cavazzini, Francesco

AU - Sgherza, Nicola

AU - Binotto, Gianni

AU - Isidori, Alessandro

AU - D’Adda, Mariella

AU - Crugnola, Monica

AU - Bosi, Costanza

AU - Heidel, Florian

AU - Molica, Matteo

AU - Scaffidi, Luigi

AU - Cattaneo, Daniele

AU - Latagliata, Roberto

AU - Auteri, Giuseppe

AU - Lemoli, Roberto M.

AU - Fanin, Renato

AU - Russo, Domenico

AU - Aversa, Franco

AU - Cuneo, Antonio

AU - Semenzato, Gianpietro

AU - Catani, Lucia

AU - Cavo, Michele

AU - Vianelli, Nicola

AU - Foà, Robin

AU - Palandri, Francesca

PY - 2019

Y1 - 2019

N2 - Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index (BMI) are significantly associated with outcome in patients who receive continuous treatment with tyrosine kinase inhibitors. We evaluated the impact of CCI and BMI on responses, drug-related toxicities, and outcome in a cohort of 402 patients with myelofibrosis (MF) treated with ruxolitinib in 23 European Hematology Centers. Comorbidities were evaluable in all 402 patients. A higher (≥ 3) CCI did not correlate with a lower spleen reduction at any time (p = 0.68) or symptoms’ response (p = 0.11), but influenced the onset of anemia during the first 3 months of treatment and later (p = 0.02 and p = 0.03, respectively) in patients without anemia baseline. BMI was evaluable in 380 patients and did not correlate with differences in spleen and symptoms response (p = 0.57 and p = 0.49, respectively). A higher CCI and a lower BMI correlated also with a reduced overall survival (p < 0.001 and p = 0.02, respectively). The achievement of a spleen response at 6 months could counterbalance the negative impact of comorbidities, while patients who were underweight when starting ruxolitinib and did not achieve a spleen response at 6 months were projected to the worse outcome. In MF patients treated with ruxolitinib, BMI and comorbidities did not influence the achievement of spleen/symptom responses, but they contributed to the early identification of patients who deserve a strict monitoring during treatment.

AB - Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index (BMI) are significantly associated with outcome in patients who receive continuous treatment with tyrosine kinase inhibitors. We evaluated the impact of CCI and BMI on responses, drug-related toxicities, and outcome in a cohort of 402 patients with myelofibrosis (MF) treated with ruxolitinib in 23 European Hematology Centers. Comorbidities were evaluable in all 402 patients. A higher (≥ 3) CCI did not correlate with a lower spleen reduction at any time (p = 0.68) or symptoms’ response (p = 0.11), but influenced the onset of anemia during the first 3 months of treatment and later (p = 0.02 and p = 0.03, respectively) in patients without anemia baseline. BMI was evaluable in 380 patients and did not correlate with differences in spleen and symptoms response (p = 0.57 and p = 0.49, respectively). A higher CCI and a lower BMI correlated also with a reduced overall survival (p < 0.001 and p = 0.02, respectively). The achievement of a spleen response at 6 months could counterbalance the negative impact of comorbidities, while patients who were underweight when starting ruxolitinib and did not achieve a spleen response at 6 months were projected to the worse outcome. In MF patients treated with ruxolitinib, BMI and comorbidities did not influence the achievement of spleen/symptom responses, but they contributed to the early identification of patients who deserve a strict monitoring during treatment.

KW - BMI

KW - CCI

KW - Comorbidities

KW - Myelofibrosis

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85057972639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057972639&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3569-1

DO - 10.1007/s00277-018-3569-1

M3 - Article

AN - SCOPUS:85057972639

VL - 98

SP - 889

EP - 896

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 4

ER -